Latest news with #ImpactDay
Yahoo
7 days ago
- Climate
- Yahoo
Maryland weather forecast: Thunderstorms, downpour possible on Aug. 13
Chief Meteorologist Tom Tasselmyer said Wednesday will be an Impact Day as the region battles evening thunderstorms and possible downpours.
Cision Canada
18-06-2025
- Business
- Cision Canada
Starlight Investments Releases 2024 Sustainability Report, Highlighting Momentum Across Key Priorities
TORONTO, June 18, 2025 /CNW/ - Starlight Investments ("Starlight") today released its 2024 Sustainability Report, detailing the company's sustainability commitments, innovative initiatives, achievements and strong progress across key impact areas. Over the past year, Starlight has continued to implement its robust multi-year Sustainability Action Plan that is founded on continuous improvement and the organization's overarching purpose – to invest with impact. "Sustainability is a central pillar of our business strategy that shapes both our long-term vision and day-to-day operations," said Glen Hirsh, Chief Operating Officer, Starlight Investments. "We are focused on actions that aim to create a lasting positive impact in the communities we serve. By prioritizing ambitious targets, transparency and engagement, we are laying the groundwork for a more sustainable and inclusive future." 2024 Sustainability Report Highlights $2.3 billion invested over five years to maintain, upgrade and expand Starlight's properties across Canada. $48.3 million invested in energy and water retrofits in 2024 alone, accelerating progress towards net zero emissions by 2050. A reduction of 21% in carbon emissions intensity and 16% in energy intensity since 2019. 1,659 new rental suites built since 2019, primarily through infill development, an approach that reduces disruption to natural ecosystems by promoting sustainable growth in existing neighbourhoods. Over $12 million invested in resident-focused amenities, from rooftop patios to community gardens, reflecting the evolving needs of families, seniors and young professionals. 1,120 rental suites reserved for vulnerable and at-risk individuals through partnerships with 40 social housing organizations. $542,000 donated to local charities, and more than 1,000 volunteer hours contributed during Starlight's annual Impact Day. Named among OnConferences' Top 50 Human Resources Team Award winners for Starlight's People & Culture team. Launched "Ivan's Garden of Hope," a children's book celebrating the diversity and experiences of Starlight's residents and embracing the power of community, distributed to thousands of families across Canada. "In 2024, we refined our Sustainability Action Plan to set more focused objectives and initiatives. Sustainability is embedded across our operations, from investment analysis to property management, and is directly linked to performance metrics," said Marlee Kohn, Vice President, ESG, Starlight Investments."Looking ahead, we remain committed to driving our sustainability program forward and moving the dial on the environmental and social priorities that matter most to our stakeholders." Commitment to Decarbonization Starlight remains steadfast in its commitment to the environment and has developed a decarbonization pathway to achieve net zero emissions intensity by 2050, with an interim target to reduce emissions by 50% by 2035 over its 2019 baseline year. To date, the company has achieved a reduction of 21% in carbon emissions intensity and 16% in energy intensity across its portfolio. Over the past year, Starlight continued to lay a strong foundation to advance this work through in-depth risk assessments, data-driven decision-making and managing properties with foresight, responsibility and care. Creating Much-Needed Housing and Vibrant Local Communities As Canada's leading rental housing provider and developer, Starlight is committed to helping address the country's housing shortage. The company is actively working to increase the supply of purpose-built rental housing, while also making significant investments in the preservation and revitalization of the country's existing and aging rental stock. Starlight has invested over $2.3 billion over the past five years in maintaining, upgrading and expanding its existing properties to ensure they remain high-quality communities for current and future residents. To date, 63% of building improvement investments are made within the first three years of ownership, and 85% over the first five years. Additionally, through community design and regular resident engagement initiatives, the company seeks to provide healthy spaces that enhance well-being and community cohesion. Starlight's approach to new purpose-built rental developments is resident-focused, thoughtfully creating safe and vibrant communities for residents to live, work and play over the long-term. Every development is designed to integrate with its neighbourhood, meeting unique community needs and enhancing resident quality of life. Starlight's innovative infill development strategy is helping address Canada's housing crisis by creating new rental supply where it is needed most, while minimizing environmental impact. The company's partnerships with social housing organizations have also delivered 1,120 affordable suites to at-risk populations, reinforcing a commitment to inclusive housing solutions. People-First Culture Drives Impact As part of its sustainability program, Starlight is also investing in its greatest asset: its people. With an emphasis on well-being, the organization expanded its wellness initiatives and mental health coverage for employees. The company continues to advance diversity and inclusion through its dedicated council, companywide training, cultural celebration days and a well-defined code of conduct. These initiatives reflect Starlight's dedication to fostering a supportive and inclusive workplace where all individuals feel valued and respected – and a culture where exceptional talent is engaged and empowered to grow. Explore Starlight's full 2024 Sustainability Report here. To learn more about Starlight's sustainability initiatives, please visit the website. About Starlight Investments Starlight Investments is a leading global real estate investment and asset management firm headquartered in Toronto, Ontario, Canada. A privately held owner, developer and asset manager of over 70,000 multi-residential suites and over 7 million square feet of commercial property space with CAD $30B AUM, Starlight offers a range of investment vehicles across various real estate strategies. Starlight's guiding mission is to balance its tenure with visionary curiosity to create positive impact for investors and communities alike. At Starlight, we invest with impact.
Yahoo
22-05-2025
- Business
- Yahoo
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of 'Maravai LifeSciencesReleases 2024 Sustainability Report'. The corrected title is 'Maravai LifeSciences Releases 2024 Sustainability Report'. Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2024 Sustainability Report, available on the Company's Sustainability webpage ( The new report highlights progress during calendar year 2024 across Maravai's four priority areas – Product Innovation, Our People, Governance, and Sustainable Growth – and underscores the Company's commitment to sustainable value creation. 'By embedding sustainability into every facet of our operations—from employee engagement to GMP scaleup — we foster innovation, strengthen our business resilience, and create long-term value for all stakeholders,' said Trey Martin, Chief Executive Officer. 'Our 2024 achievements position Maravai to remain our customers' first choice as they advance their programs in next-generation therapeutics and diagnostics.' Key highlights from the 2024 report include: Product Innovation Launched 49 new products across portfolio brands, including CleanCap® M6 analog now available at GMP quality Completed state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold Established RNA Innovation Center in collaboration with Johns Hopkins University Added to our GMP manufacturing expertise and have now manufactured over 130 GMP batches for mRNA Our People Achieved 95% participation rate in our annual employee engagement survey, receiving over 2,600 comments Expanded WE (We are Empowered) Employee Resource Group to facilitate advocacy, mentorship, and outreach across the organization Implemented new career framework creating transparent progression paths for all employees Continued our Impact Day program throughout 2024, with employees contributing approximately 800 volunteer hours Governance Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman of the Board Adopted formal, publicly available Human Rights Policy 100% of standing Board Committees chaired by independent members Strengthened intellectual property position with additional CleanCap® patents in China and Canada Sustainable Growth Enhanced greenhouse gas emissions data collection and expanded Scope 3 emissions reporting Leland, North Carolina facility's solar panels generated over 180,000 kWh, offsetting approximately 20% of facility's energy use San Diego EV charging stations helped save over 19,000 gallons of gasoline Advanced planning for lab plastics recycling program and single-use plastic phase-out The 2024 report was prepared in reference to the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB) and Greenhouse Gas Protocol frameworks and maps selected disclosures to relevant U.N. Sustainable Development Goals (SDGs). About Maravai Maravai LifeSciences is an innovative lifesciences company that provides critical products to enable the development of breakthrough therapeutics, vaccines, cell and gene therapies and diagnostics. Through its TriLink BioTechnologies, Glen Research, Alphazyme and Cygnus Technologies brands, Maravai delivers complex nucleic acid chemistries, differentiated mRNA and enzyme solutions, and gold standard biologics safety tests to a global customer base spanning large pharmaceutical companies, emerging biotechs and leading academic institutions. Forward Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements related to future product offerings, facility capabilities, and sustainability initiatives. Forward-looking statements are neither historical facts nor assurances of future performance and are subject to risks and uncertainties that could cause actual results to differ materially. A detailed discussion of these risks is included in Maravai's most recent Annual Report on Form 10K and subsequent filings with the U.S. Securities and Exchange Commission. Maravai undertakes no obligation to update forward-looking statements except as required by law. CONTACT: Contact Information: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@
Yahoo
21-05-2025
- Business
- Yahoo
CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the incorrect title of 'Maravai LifeSciencesReleases 2024 Sustainability Report'. The corrected title is 'Maravai LifeSciences Releases 2024 Sustainability Report'. Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2024 Sustainability Report, available on the Company's Sustainability webpage ( The new report highlights progress during calendar year 2024 across Maravai's four priority areas – Product Innovation, Our People, Governance, and Sustainable Growth – and underscores the Company's commitment to sustainable value creation. 'By embedding sustainability into every facet of our operations—from employee engagement to GMP scaleup — we foster innovation, strengthen our business resilience, and create long-term value for all stakeholders,' said Trey Martin, Chief Executive Officer. 'Our 2024 achievements position Maravai to remain our customers' first choice as they advance their programs in next-generation therapeutics and diagnostics.' Key highlights from the 2024 report include: Product Innovation Launched 49 new products across portfolio brands, including CleanCap® M6 analog now available at GMP quality Completed state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold Established RNA Innovation Center in collaboration with Johns Hopkins University Added to our GMP manufacturing expertise and have now manufactured over 130 GMP batches for mRNA Our People Achieved 95% participation rate in our annual employee engagement survey, receiving over 2,600 comments Expanded WE (We are Empowered) Employee Resource Group to facilitate advocacy, mentorship, and outreach across the organization Implemented new career framework creating transparent progression paths for all employees Continued our Impact Day program throughout 2024, with employees contributing approximately 800 volunteer hours Governance Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman of the Board Adopted formal, publicly available Human Rights Policy 100% of standing Board Committees chaired by independent members Strengthened intellectual property position with additional CleanCap® patents in China and Canada Sustainable Growth Enhanced greenhouse gas emissions data collection and expanded Scope 3 emissions reporting Leland, North Carolina facility's solar panels generated over 180,000 kWh, offsetting approximately 20% of facility's energy use San Diego EV charging stations helped save over 19,000 gallons of gasoline Advanced planning for lab plastics recycling program and single-use plastic phase-out The 2024 report was prepared in reference to the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB) and Greenhouse Gas Protocol frameworks and maps selected disclosures to relevant U.N. Sustainable Development Goals (SDGs). About Maravai Maravai LifeSciences is an innovative lifesciences company that provides critical products to enable the development of breakthrough therapeutics, vaccines, cell and gene therapies and diagnostics. Through its TriLink BioTechnologies, Glen Research, Alphazyme and Cygnus Technologies brands, Maravai delivers complex nucleic acid chemistries, differentiated mRNA and enzyme solutions, and gold standard biologics safety tests to a global customer base spanning large pharmaceutical companies, emerging biotechs and leading academic institutions. Forward Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements related to future product offerings, facility capabilities, and sustainability initiatives. Forward-looking statements are neither historical facts nor assurances of future performance and are subject to risks and uncertainties that could cause actual results to differ materially. A detailed discussion of these risks is included in Maravai's most recent Annual Report on Form 10K and subsequent filings with the U.S. Securities and Exchange Commission. Maravai undertakes no obligation to update forward-looking statements except as required by law. CONTACT: Contact Information: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
Maravai LifeSciencesReleases 2024 Sustainability Report
Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech innovators through its portfolio companies TriLink BioTechnologies, Glen Research, Alphazyme, and Cygnus Technologies, today announced the publication of its 2024 Sustainability Report, available on the Company's Sustainability webpage ( The new report highlights progress during calendar year 2024 across Maravai's four priority areas – Product Innovation, Our People, Governance, and Sustainable Growth – and underscores the Company's commitment to sustainable value creation. 'By embedding sustainability into every facet of our operations—from employee engagement to GMP scaleup — we foster innovation, strengthen our business resilience, and create long-term value for all stakeholders,' said Trey Martin, Chief Executive Officer. 'Our 2024 achievements position Maravai to remain our customers' first choice as they advance their programs in next-generation therapeutics and diagnostics.' Key highlights from the 2024 report include: Product Innovation Launched 49 new products across portfolio brands, including CleanCap® M6 analog now available at GMP quality Completed state-of-the-art GMP facility in San Diego, increasing mRNA production capacity tenfold Established RNA Innovation Center in collaboration with Johns Hopkins University Added to our GMP manufacturing expertise and have now manufactured over 130 GMP batches for mRNA Our People Achieved 95% participation rate in our annual employee engagement survey, receiving over 2,600 comments Expanded WE (We are Empowered) Employee Resource Group to facilitate advocacy, mentorship, and outreach across the organization Implemented new career framework creating transparent progression paths for all employees Continued our Impact Day program throughout 2024, with employees contributing approximately 800 volunteer hours Governance Appointed healthcare industry veteran R. Andrew Eckert as independent Chairman of the Board Adopted formal, publicly available Human Rights Policy 100% of standing Board Committees chaired by independent members Strengthened intellectual property position with additional CleanCap® patents in China and Canada Sustainable Growth Enhanced greenhouse gas emissions data collection and expanded Scope 3 emissions reporting Leland, North Carolina facility's solar panels generated over 180,000 kWh, offsetting approximately 20% of facility's energy use San Diego EV charging stations helped save over 19,000 gallons of gasoline Advanced planning for lab plastics recycling program and single-use plastic phase-out The 2024 report was prepared in reference to the Global Reporting Initiative (GRI), Sustainability Accounting Standards Board (SASB) and Greenhouse Gas Protocol frameworks and maps selected disclosures to relevant U.N. Sustainable Development Goals (SDGs). About Maravai Maravai LifeSciences is an innovative lifesciences company that provides critical products to enable the development of breakthrough therapeutics, vaccines, cell and gene therapies and diagnostics. Through its TriLink BioTechnologies, Glen Research, Alphazyme and Cygnus Technologies brands, Maravai delivers complex nucleic acid chemistries, differentiated mRNA and enzyme solutions, and gold standard biologics safety tests to a global customer base spanning large pharmaceutical companies, emerging biotechs and leading academic institutions. Forward Looking Statements This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, including statements related to future product offerings, facility capabilities, and sustainability initiatives. Forward-looking statements are neither historical facts nor assurances of future performance and are subject to risks and uncertainties that could cause actual results to differ materially. A detailed discussion of these risks is included in Maravai's most recent Annual Report on Form 10K and subsequent filings with the U.S. Securities and Exchange Commission. Maravai undertakes no obligation to update forward-looking statements except as required by law. CONTACT: Contact Information: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@ in to access your portfolio
